Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The long-term investment activity ratios exhibit varied trends over the observed period. Net fixed asset turnover demonstrates a general declining trend, while total asset turnover initially remains stable before showing a more pronounced increase in later periods. Equity turnover experiences a substantial and accelerating increase towards the end of the analyzed timeframe.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio begins at 11.18 and generally decreases over the period, reaching 10.87. While fluctuations occur, the overall trajectory indicates diminishing efficiency in generating revenue from fixed assets. The decline is relatively gradual through December 2022, then stabilizes before a slight decrease in the final reported period. This suggests a potential need to evaluate fixed asset utilization strategies.
- Total Asset Turnover
- Total asset turnover remains relatively consistent around 0.40 to 0.42 from March 2022 to September 2023. A noticeable decrease to 0.37 is observed in March 2024, followed by a recovery to 0.42 in December 2024. Subsequently, the ratio increases significantly, reaching 0.46 by December 2025. This indicates improving efficiency in utilizing all assets to generate revenue in the latter part of the period, potentially due to changes in asset management or sales strategies.
- Equity Turnover
- Equity turnover shows a more dynamic pattern. It increases from 3.48 in March 2022 to 5.24 in December 2022. This upward trend accelerates dramatically in 2024 and 2025, with the ratio escalating to 16.94 in December 2024, 40.40 in March 2025, and remaining unreported for subsequent periods. This substantial increase suggests a significant rise in revenue generated per dollar of equity, potentially indicating improved profitability or a change in capital structure. The lack of reported values for June and September 2025 warrants further investigation.
In summary, while fixed asset utilization appears to be declining, the company demonstrates improving overall asset and equity efficiency, particularly in the most recent periods. The significant increase in equity turnover is a key observation and merits further scrutiny to understand the underlying drivers and sustainability of this trend.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net revenues | |||||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net fixed asset turnover
= (Net revenuesQ4 2025
+ Net revenuesQ3 2025
+ Net revenuesQ2 2025
+ Net revenuesQ1 2025)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio experienced a generally declining trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a relatively stable performance, followed by a gradual decrease and some fluctuation in later periods. A detailed examination of the ratio’s behavior is presented below.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The ratio began at 11.18 and demonstrated a slight increase, peaking at 11.82 in September 2022, before settling at 11.76 by the end of the year. This suggests a consistent ability to generate revenue from its fixed assets during this timeframe, with a minor improvement in asset utilization observed mid-year.
- Subsequent Decline (Mar 31, 2023 – Dec 31, 2023)
- A noticeable downward trend emerged in 2023. The ratio decreased from 11.51 in March to 10.89 in December. This indicates a diminishing efficiency in utilizing fixed assets to generate revenue. The decline was not uniform, with some quarterly fluctuations, but the overall direction was consistently downward.
- Stabilization and Fluctuations (Mar 31, 2024 – Jun 30, 2025)
- From 2024 through the first half of 2025, the ratio exhibited more stability, fluctuating between 10.80 and 11.04. While not demonstrating significant recovery, the rate of decline slowed. The ratio ended the period at 11.04 in June 2025, before decreasing slightly to 10.87 by December 2025. This suggests that the factors contributing to the earlier decline may have stabilized, but a full reversal has not occurred.
- Overall Trend
- The overall trend reveals a decrease in the net fixed asset turnover ratio from approximately 11.18 to 10.87 over the analyzed period. While revenue generally increased over the period, the growth in property and equipment, net, outpaced revenue growth, resulting in the observed decline. This could indicate increased investment in fixed assets without a corresponding proportional increase in revenue generation, or potentially, a less efficient utilization of existing assets.
Further investigation into the underlying drivers of these changes, such as specific asset investments and revenue streams, would be necessary to provide a more comprehensive understanding of the observed trends.
Total Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net revenues | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Total asset turnover
= (Net revenuesQ4 2025
+ Net revenuesQ3 2025
+ Net revenuesQ2 2025
+ Net revenuesQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio for the analyzed period demonstrates a generally stable pattern with some fluctuation. Initially, the ratio held steady at 0.40 for the first two quarters, then experienced a slight increase to 0.42 before stabilizing around 0.40 to 0.41 for several subsequent quarters. A noticeable downward shift occurred in the first quarter of 2024, with the ratio decreasing to 0.37. This was followed by a partial recovery to 0.39 in the subsequent quarter, before returning to 0.42. The final four quarters show a consistent upward trend, culminating in a ratio of 0.46.
- Overall Trend
- The overall trend indicates a relatively efficient use of assets to generate revenue, with a slight improvement observed in the latter part of the analyzed period. The ratio generally remained within a narrow band between 0.37 and 0.45, suggesting consistent operational performance. The recent increase suggests improving asset utilization.
- Short-Term Fluctuations
- Short-term fluctuations are present, particularly the dip to 0.37 in the first quarter of 2024. This decrease could be attributed to a temporary decline in net revenues relative to total assets, or potentially an increase in total assets without a corresponding increase in revenue. The subsequent recovery suggests this was a temporary anomaly.
- Recent Performance
- The most recent quarters (March 31, 2025 – December 31, 2025) demonstrate a clear upward trend in the total asset turnover ratio, increasing from 0.42 to 0.46. This indicates a strengthening ability to generate sales from its asset base, potentially due to improved operational efficiency or strategic asset management.
- Comparison to Initial Period
- Comparing the beginning of the period (0.40) to the end (0.46), the ratio has increased by 15%. This suggests that the company is becoming more effective at utilizing its assets to generate revenue over the long term. However, the fluctuations throughout the period indicate that this improvement is not linear.
Equity Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net revenues | |||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Equity turnover
= (Net revenuesQ4 2025
+ Net revenuesQ3 2025
+ Net revenuesQ2 2025
+ Net revenuesQ1 2025)
÷ Stockholders’ equity (deficit)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio demonstrates a significant and evolving pattern over the observed period. Initially, the ratio fluctuates between 3.36 and 4.56 from March 2022 through September 2023, indicating a relatively consistent level of net revenues generated per dollar of stockholders’ equity. However, a marked increase begins in December 2023 and continues through March 2025, revealing a substantial shift in the relationship between net revenues and stockholders’ equity.
- Initial Period (Mar 31, 2022 – Sep 30, 2023)
- During this timeframe, the equity turnover ratio exhibits moderate variability. It begins at 3.48, peaks at 4.56, and generally remains within a range of approximately one unit. This suggests a stable, though not exceptionally high, efficiency in utilizing equity to generate revenue.
- Accelerated Increase (Dec 31, 2023 – Mar 31, 2025)
- A dramatic increase in the equity turnover ratio is observed starting in December 2023. The ratio rises from 5.24 to an exceptionally high value of 40.40 by March 2025. This surge coincides with a significant decrease in stockholders’ equity, while net revenues remain relatively stable or increase modestly. The substantial rise indicates that each dollar of stockholders’ equity is generating a considerably larger amount of revenue than in previous periods.
The increasing trend is largely driven by the declining stockholders’ equity. While net revenues show some growth, the magnitude of the equity turnover increase suggests that the reduction in equity is the primary factor. Further investigation would be required to understand the reasons behind the decreasing equity, such as share repurchases, dividend payouts, or accumulated losses, and to assess the sustainability of this elevated turnover ratio.
- Potential Considerations
- The extremely high equity turnover ratio in the latter part of the period warrants careful scrutiny. While a higher ratio can indicate efficient equity utilization, an excessively high value may also signal financial risk or unsustainable practices. The negative equity position observed in June and September 2025 further emphasizes the need for detailed analysis of the underlying financial health of the entity.